Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
Rhea-AI Summary
Prime Medicine, Inc. (Nasdaq: PRME) will participate in the 27th Annual Milken Institute Global Conference with its CEO, Dr. Keith Gottesdiener, discussing cutting-edge technologies and scientific breakthroughs. The panel aims to offer insights into the future and will be livestreamed on May 8, 2024.
Positive
- None.
Negative
- None.
News Market Reaction – PRME
On the day this news was published, PRME gained 7.11%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a panel discussion at the 27th Annual Milken Institute Global Conference entitled “Things That Will Blow Your Mind.” The panel will bring together innovators across multiple disciplines to discuss cutting-edge technologies, inventions, and scientific breakthroughs, and to share a glimpse of what the future will look like.
The Conference will take place May 5-8, 2024, in Los Angeles, California and the panel discussion will be held on Wednesday, May 8, 2024, at 8:30 a.m. PT (11:30 a.m. ET). A livestream will be available at www.milkeninstitute.org.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around core areas of focus: hematology and immunology, liver, lung, ocular and neuromuscular. Across each core area, Prime Medicine’s initial focus is on genetic diseases with a fast, direct path to treating patients, and those with high unmet need not currently addressable using other gene editing approaches. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential to expand beyond the genetic diseases in its initial pipeline, potentially including immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com
FAQ
When will Prime Medicine participate in the 27th Annual Milken Institute Global Conference?
Who will represent Prime Medicine at the conference?
What is the theme of the panel discussion at the conference?
Where will the conference take place?
Will the panel discussion be livestreamed?
What time will the panel discussion take place?
